Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer
On Friday, Clovis Oncology (NASDAQ: CLVS) gained Food and Drug Administration approval of Rubraca for patients with metastatic castration-resistant prostate tumors that have BRCA mutations.
Rubraca inhibits poly ADP-ribose polymerase (PARP) proteins that are involved in the repair of DNA. By itself, inhibition of PARP doesn't do much, but inhibiting the repair proteins in the presence of mutations in BRCA proteins, which are also responsible for repairing DNA, results in enough damage to cancer cells' DNA that the tumor cells ultimately die.
Image source: Getty Images.
Source Fool.com
